Bioqual, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023
April 21, 2023 at 12:17 pm EDT
Share
Bioqual, Inc. reported earnings results for the third quarter and nine months ended February 28, 2023. For the third quarter, the company reported sales was USD 14.11 million compared to USD 17.13 million a year ago. Net loss was USD 1.14 million compared to net income of USD 0.856588 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to basic earnings per share from continuing operations of USD 0.96 a year ago. Diluted loss per share from continuing operations was USD 1.27 compared to diluted earnings per share from continuing operations of USD 0.96 a year ago.
For the nine months, sales was USD 46.6 million compared to USD 47.81 million a year ago. Net income was USD 1.54 million compared to USD 3.37 million a year ago. Basic earnings per share from continuing operations was USD 1.72 compared to USD 3.77 a year ago. Diluted earnings per share from continuing operations was USD 1.72 compared to USD 3.77 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
